150 related articles for article (PubMed ID: 25016807)
21. JAK2 inhibitors: are they the solution?
Santos FP; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S28-36. PubMed ID: 22035745
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
Bhagwat N; Levine RL; Koppikar P
Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
[TBL] [Abstract][Full Text] [Related]
23. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
Bartalucci N; Tozzi L; Bogani C; Martinelli S; Rotunno G; Villeval JL; Vannucchi AM
J Cell Mol Med; 2013 Nov; 17(11):1385-96. PubMed ID: 24237791
[TBL] [Abstract][Full Text] [Related]
24. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.
Passamonti F; Maffioli M; Caramazza D; Cazzola M
Oncotarget; 2011 Jun; 2(6):485-90. PubMed ID: 21646683
[TBL] [Abstract][Full Text] [Related]
25. Preclinical and clinical activity of ATP mimetic JAK2 inhibitors.
Wadleigh M; Tefferi A
Clin Adv Hematol Oncol; 2010 Aug; 8(8):557-63. PubMed ID: 20966892
[TBL] [Abstract][Full Text] [Related]
26. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
[TBL] [Abstract][Full Text] [Related]
28. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
29. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
[TBL] [Abstract][Full Text] [Related]
30. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
[TBL] [Abstract][Full Text] [Related]
31. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Tyner JW; Bumm TG; Deininger J; Wood L; Aichberger KJ; Loriaux MM; Druker BJ; Burns CJ; Fantino E; Deininger MW
Blood; 2010 Jun; 115(25):5232-40. PubMed ID: 20385788
[TBL] [Abstract][Full Text] [Related]
32. Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Fernández-Rodríguez C; Besses C
Br J Haematol; 2016 Feb; 172(4):639-42. PubMed ID: 26115187
[No Abstract] [Full Text] [Related]
33. JAK2 kinase inhibitors and myeloproliferative disorders.
Chen AT; Prchal JT
Curr Opin Hematol; 2010 Mar; 17(2):110-6. PubMed ID: 20087176
[TBL] [Abstract][Full Text] [Related]
34. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
35. Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells.
Cheng Z; Fu J; Liu G; Zhang L; Xu Q; Wang SY
Leuk Lymphoma; 2018 Jan; 59(1):196-203. PubMed ID: 28554272
[TBL] [Abstract][Full Text] [Related]
36. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
37. Novel strategies for patients with chronic myeloproliferative disorders.
Barosi G; Rosti V
Curr Opin Hematol; 2009 Mar; 16(2):129-34. PubMed ID: 19468275
[TBL] [Abstract][Full Text] [Related]
38. The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases.
Hitoshi Y; Lin N; Payan DG; Markovtsov V
Int J Hematol; 2010 Mar; 91(2):189-200. PubMed ID: 20191331
[TBL] [Abstract][Full Text] [Related]
39. JAK2 inhibitors: what's the true therapeutic potential?
Santos FP; Verstovsek S
Blood Rev; 2011 Mar; 25(2):53-63. PubMed ID: 21095048
[TBL] [Abstract][Full Text] [Related]
40. Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.
Tibes R; Mesa RA
J Hematol Oncol; 2014 Mar; 7():18. PubMed ID: 24598114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]